GRI Bio, Inc. (GRI)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.63
- As of
Kresmion compiles this page from GRI's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
GRI Bio, Inc. (GRI): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-08.
See the full GRI dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for GRI on one page. Preview it with sample data, then open it live with a free account.
Preview the GRI dossierActive events for GRI
- mediumEarnings above estimates
Q2-2026: Beat consensus by 24.6%, EPS $-0.91 vs $-1.207 estimate
- medium13F: new position
CITADEL ADVISORS LLC new position in GRI
- mediumEarnings below estimates
Q3-2025: Missed consensus by 36.3% - EPS $-35.84 vs $-26.3004 estimate
- mediumEarnings below estimates
Q4-2025: Missed consensus by 294.6% - EPS $-116.61 vs $-29.5526 estimate
- mediumEarnings below estimates
Q1-2026: Missed consensus by 76.1% - EPS $-1.61 vs $-0.9141 estimate
FREE, NO ACCOUNT
Every event on GRI, as it fires
New filings, 13F moves and cross asset events on GRI land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in GRI (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 3622AW502 · 2026Q2 | $24K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, GRI
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
GRI against its peers
GRI's return on equity of -199.0% ranks in the 41st percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-04-30.
| Metric | GRI | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 63167 | n/a | 10 |
| Gross margin | n/a | 80.6% | n/a | 7 |
| Operating margin | n/a | -1186.4% | n/a | 8 |
| Net margin | n/a | -1576.2% | n/a | 8 |
| Return on equity | -199.0% | -121.5% | 41 | 15 |
Peers (19): KALA, JUNS, CVKD, PMCB, ERNA, SXTP, CMND, EOCN, BCAB, APTOF.D, SILO, APVO, NCNA, DRMA, EMMA, XBIO, LSBCF.D, MBIO, HCWB. Left out: BVAXF (no annual filing), NYMXF (period gap), LIMN (no annual filing), ENLV (no annual filing), NRSN (no annual filing), XTLB (period gap). Fiscal periods ending between 2025-03-31 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (GRI: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow GRI on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to GRI for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.